Authors
Latest:
Dr. Sezer on the FDA Approval of Cemiplimab in Frontline Advanced NSCLC With High PD-L1 ExpressionAhmet Sezer, MD, professor, Department of Medical Oncology, Başkent University, Adana, Turkey, discusses the FDA approval of cemiplimab-rwlc (Libtayo) as frontline treatment for patients with advanced non–small cell lung cancer (NSCLC) and high PD-L1 expression.
Latest:
Kummar on the Investigation of Rezatapopt in TP53 Y220C–Mutated Advanced Solid TumorsDr Kummar discusses the significance of targeting TP53 Y220C in solid tumors and early data reported with rezatapopt in TP53 Y220C–mutant solid tumors.
Latest:
Dr. Siena on the Rationale for the DESTINY-CRC01 in Metastatic CRCSalvatore Siena, MD, discusses the rationale for the phase 2 DESTINY-CRC01 trial in metastatic colorectal cancer.
Latest:
18F-FDG PET/CT May Serve as Early Interval Response Assessment Tool in Patients Receiving Combinatorial ICI TherapyFunctional imaging information from 18F-FDG PET can complement data from anatomic imaging studies from CT and MRI to predict response to ICI therapy.
Latest:
Dr Vaishampayan on the Rationale For the SWOG-1931/PROBE Trial in Advanced RCCUlka Nitin Vaishampayan, MBBS, discusses the rationale for conducting the phase 3 SWOG 1931 trial in patients with advanced renal cell carcinoma.
Latest:
Dr. Palmbos on the Utilization of Nivolumab Following Cystectomy in Muscle-Invasive Bladder CancerPhillip Palmbos, MD, PhD, discusses the utilization of adjuvant nivolumab following cystectomy in high-risk, muscle-invasive bladder cancer.
Latest:
Second-Line Treatment of SCLCVamsidhar Velcheti, MD, leads the discussion on the current standard of care and approaching the treatment of second-line SCLC.
Latest:
Metastatic Urothelial Carcinoma: Unmet Needs and Future DirectionsExpert reflection on the current unmet needs in metastatic urothelial carcinoma and hope for future improvements in the treatment armamentarium.
Latest:
Dr. Milhem on the Utility of RP1 in Solid TumorsMohammed Milhem, MBBS, MBBS, discusses the utility of vusolimogeneoderparepvec in solid tumors.
Latest:
Dr. Zalcberg on the Rationale for Dose Escalation With Ripretinib in Advanced GISTJohn Raymond Zalcberg, PhD, MBBS, discusses the rationale for intra-patient dose escalation with ripretinib, as was examined in the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.
Latest:
Comprehensive Treatment Advances Care for Patients With Early-Stage Breast CancerAdvances in the diagnosis and treatment of early-stage breast cancer highlight the need for clinicians to adapt to paradigm shifts that will have notable effects on patient care.
Latest:
Dr. Khetrapal on Intracorporeal Robotic vs Open Cystectomy in MIBCPramit Khetrapal, MD, discusses the results of evaluating intracorporeal robotic vs open cystectomy in a multicenter, randomized trial in patients with muscle-invasive bladder cancer.
Latest:
Palliative Care Builds Bridges in Oncology PracticeToby Campbell, MD, MSCI, discusses the nuances of palliative care in oncology.
Latest:
The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and MortalityOne of the prime risk factors for CRC is the consumption of a high-risk, Western-style diet high in processed foods, refined grains, red meat, and sugar.
Latest:
Dr Monga on the Background of Investigating PRT811 in Glioma and MelanomaVarun Monga, MD, discusses the background for investigating the protein arginine methyltransferase 5 brain-penetrant inhibitor PRT811 in a phase 1 study in patients with recurrent high-grade glioma or uveal melanoma, as well as the agent’s mechanism of action.
Latest:
Dr Asai on Final Results From a Phase 1/2 Trial of Tirabrutinib in R/R PCNSLKatsunori Asai, MD, PhD, Department of Neurosurgery, Osaka International Cancer Institute, Osaka, Japan, discusses the use of tirabrutinib in patients with relapsed/refractory primary central nervous system lymphoma according to a phase 1/2 study (JapicCTI-173646).
Latest:
Nonmetastatic CRPC: Treatment SelectionAn in-depth discussion regarding experience treating nonmetastatic castration-resistant prostate cancer (CRPC) with apalutamide, enzalutamide, and darolutamide, and factors that impact treatment selection.
Latest:
Dr. Merchant on the Importance of Continued Care in Pediatric CraniopharyngiomaThomas E. Merchant, DO, PhD, discusses the importance of continued care in pediatric patients with craniopharyngioma.
Latest:
Dr. Bociek on the Clinical Uncertainty of MRD Negativity in CLLR. Gregory Bociek, MD, discusses the clinical uncertainty of minimal residual disease negativity in chronic lymphocytic leukemia.
Latest:
Dr. Slomovitz on the Key Objectives of the KEYNOTE-B21 Trial in High-Risk Endometrial CancerBrian M. Slomovitz, discusses the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial.
Latest:
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell TransplantJeremy L. Ramdial, MD, discusses the myeloablative conditioning regimen gemcitabine, clofarabine, and busulfan in patients with aggressive lymphomas.
Latest:
Dr. Mehta-Shah on the Variations of the CHOP Regimen in PTCLNeha Mehta-Shah, MD, MSCI, discusses variations of CHOP-based chemotherapy in peripheral T-cell lymphoma.
Latest:
Evidence Supports Value of Physical Activity in Patients With CancerBaseline physical activity and physical function prior to a cancer diagnosis or treatment affects survival, with evidence spanning across solid tumor types and hematologic malignancies.
Latest:
Dr Sharifi on the Importance of ctDNA Testing in Breast CancerMarina Sharifi, MD, PhD, discusses the benefit of utilizing personalized and targeted therapy approaches in the treatment of patients with breast cancer.
Latest:
Dr Sriramareddy on the Relationship Between Uveal Melanoma and the Liver MetastasesSathya Neelature Sriramareddy, MD, PhD, discusses how the interaction between uveal melanoma cells and the liver microenvironment could influence metastasis growth and therapeutic response.
Latest:
Dr. Starr on the Characterization of POLE/POLD1 Mutations in Colorectal AdenocarcinomaJason Starr, DO, discusses the characterization of POLE/POLD1 mutations in colorectal adenocarcinoma.
Latest:
Dr Weiss on the Ongoing Investigation of Tebentafusp With or Without Pembrolizumab in Non-Uveal MelanomaSarah Weiss, MD, discusses the ongoing phase 2/3 TEBE-AM trial of tebentafusp with or without pembrolizumab in a subset of pretreated patients with non-uveal melanoma.
Latest:
Strategic Approaches to Biomarker Testing in NSCLC: Optimal TimingExperts reflect on the evolving landscape of biomarker testing in lung cancer, examining its crucial role in treatment decisions and advancements in perioperative and adjuvant therapies.
.jpg?fit=crop&auto=format)
